Viking Therapeutics, Inc. (NASDAQ: VKTX) today announced the presentation of results from the company's 12-week Phase 2 study of VK2809 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA Management Comments

Viking Therapeutics Presents Results from Phase 2 Study of VK2809 in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-Cholesterol in Oral Late-Breaker Presentation at The LiverNovember 12, 2018 6:55 PM Viking Therapeutic (VKTX) PT Lowered to $22.50 at Roth CapitalNovember 9, 2018 11:02 AM